 Complement C3
"Complement C3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase.
| Descriptor ID |
D003176
|
| MeSH Number(s) |
D12.776.124.050.140 D12.776.124.486.274.250
|
| Concept/Terms |
Complement C3- Complement C3
- C3, Complement
- Complement 3
- Complement Component 3
- Component 3, Complement
- C3 Complement
- Complement, C3
Complement C3 Precursor- Complement C3 Precursor
- C3 Precursor, Complement
- Precursor, Complement C3
- Pro-C3
- Pro C3
- Precursor-Complement 3
- Precursor Complement 3
- Pro-Complement 3
- Pro Complement 3
- C3 Precursor
- Precursor, C3
|
Below are MeSH descriptors whose meaning is more general than "Complement C3".
Below are MeSH descriptors whose meaning is more specific than "Complement C3".
This graph shows the total number of publications written about "Complement C3" by people in this website by year, and whether "Complement C3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 2 | 1 | 3 | | 2000 | 1 | 2 | 3 | | 2001 | 2 | 2 | 4 | | 2002 | 1 | 4 | 5 | | 2003 | 1 | 3 | 4 | | 2004 | 1 | 3 | 4 | | 2005 | 0 | 3 | 3 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 2 | 4 | | 2008 | 3 | 2 | 5 | | 2009 | 0 | 2 | 2 | | 2011 | 3 | 3 | 6 | | 2012 | 1 | 2 | 3 | | 2013 | 3 | 5 | 8 | | 2014 | 2 | 1 | 3 | | 2015 | 2 | 1 | 3 | | 2016 | 4 | 2 | 6 | | 2017 | 1 | 5 | 6 | | 2018 | 3 | 2 | 5 | | 2019 | 2 | 2 | 4 | | 2020 | 1 | 3 | 4 | | 2021 | 2 | 4 | 6 | | 2022 | 2 | 2 | 4 | | 2023 | 0 | 2 | 2 | | 2024 | 0 | 1 | 1 | | 2025 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement C3" by people in Profiles.
-
Barbour SJ, Hladunewich MA, McCaleb ML, Robson R, Barrett TD, Yin L, Frazer-Abel A, Garg JP, Geary R, Schneider E, Brice GT. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2026 Mar; 109(3):592-601.
-
Fakhouri F, Bomback AS, Ariceta G, Delmas Y, Dixon BP, Gale DP, Greenbaum LA, Han SH, Isbel N, Le Quintrec M, Licht C, Mastrangelo A, Mizuno M, Neves de Holanda MI, Pickering MC, Remuzzi G, Van De Kar N, Vivarelli M, Walker PD, Wallace D, Zecher D, Francois C, Deschatelets P, Li L, Wang Z, Abad-Franch L, Kinnman N, López-Lázaro L, Szamosi J, Nester CM. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025 Dec 04; 393(22):2210-2220.
-
Wheeler EA, Lenhart-Pendergrass PM, Rysavy NM, Poch KR, Caceres SM, Calhoun KM, Serban KA, Nick JA, Malcolm KC. Divergent host humoral innate immune response to the smooth-to-rough adaptation of Mycobacterium abscessus in chronic infection. Front Cell Infect Microbiol. 2025; 15:1445660.
-
Prasad RR, Kumar S, Zhang H, Li M, Hu CJ, Riddle S, McKeon BA, Frid MG, Hoetzenecker K, Crnkovic S, Kwapiszewska G, Tuder RM, Stenmark KR. An intracellular complement system drives metabolic and proinflammatory reprogramming of vascular fibroblasts in pulmonary hypertension. JCI Insight. 2025 Feb 13; 10(6).
-
Li Y, Saba L, Scheinman RI, Banda NK, Holers M, Monte A, Dylla L, Moghimi SM, Simberg D. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. ACS Nano. 2024 10 22; 18(42):28649-28658.
-
Li Y, Jacques S, Gaikwad H, Wang G, Banda NK, Holers VM, Scheinman RI, Tomlinson S, Moghimi SM, Simberg D. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. Nat Nanotechnol. 2024 Feb; 19(2):246-254.
-
Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024 May; 39(5):1387-1404.
-
Podos SD, Trachtman H, Appel GB, Bomback AS, Dixon BP, Wetzels JFM, Cook HT, Parikh SV, Pickering MC, Tumlin J, Langman CB, Lightstone L, Sperati CJ, Daina E, Bouman KP, Rice K, Thanassi JA, Huang M, Nester C, Remuzzi G. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. Am J Nephrol. 2022; 53(10):675-686.
-
Thurman JM, Harrison RA. The susceptibility of the kidney to alternative pathway activation-A hypothesis. Immunol Rev. 2023 01; 313(1):327-338.
-
Fahnoe KC, Liu F, Morgan JG, Ryan ST, Storek M, Stark EG, Taylor FR, Holers VM, Thurman JM, Wawersik S, Kalled SL, Violette SM. Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue. Front Immunol. 2022; 13:869725.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|